Equity Profile

MIRM

Mirum Pharmaceuticals, Inc.

Health CareBiotechnology$5.7B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MIRM Q2-2026 Earnings Preview

Context

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for rare diseases. With a market cap of $6 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

In Q1-2026, Mirum reported an EPS of -$13.43, missing expectations significantly. Despite this, the stock rose by 4.04% the next day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Mirum's upcoming earnings are uncertain due to the lack of analyst estimates and management guidance. Investors are likely looking for any signs of recovery or progress in the pipeline.

Bull Case

If Mirum can demonstrate significant progress in its drug pipeline or show unexpected revenue growth, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company continues to report large losses or fails to provide clarity on its future prospects, it could lead to a negative response from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and expected timelines for upcoming trials?

Investors will closely watch for any updates that could indicate future revenue potential or setbacks.

How does the company plan to address the significant losses reported in the last quarter?

Understanding the company's strategy for managing expenses and improving profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Mirum's pipeline to deliver unexpected results, particularly given the recent trends in biotech where innovative therapies can rapidly gain traction.

Supporting Evidence

The options market is pricing a 37.56% move, indicating expectations of volatility that may not align with historical performance.

Insider selling activity could suggest a lack of confidence in the near-term outlook, which the market may not fully appreciate.

Key Risk

If the company provides a clear and compelling update on its pipeline, it could shift the market's perception significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around whether Mirum can turn its financial performance around and make progress in its drug development pipeline.

Bull Confirmed If

Demonstrating a clear path to profitability with reduced losses or positive revenue growth would confirm the bull case.

Bear Confirmed If

Continued large losses without a clear strategy for improvement would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±37.56%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±37.6% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

56.0%

Calls (10K)P/C Ratio: 3.33Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$193,800.00

2,000 sh

1 insider

Net

$193,800.00

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum beats expectations and raises guidance, history suggests the stock could rise by around 1.33%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may see muted movement as investors reassess.

Miss

Should the company miss expectations again, history suggests an average decline of around 0.31%, indicating a negative reaction.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for clinical trials in the drug pipeline.
2Details on cost management strategies to address recent losses.
3Insights into market demand for their current and upcoming products.
4Comments on competitive landscape and how Mirum plans to differentiate itself.
5Any potential partnerships or collaborations that could enhance growth prospects.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Mirum Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and generate sales from its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MIRM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-680.75%

Avg Stock Reaction

+0.82%

Last Quarter Recap

In Q1-2026, Mirum reported an EPS of -$13.43, missing expectations significantly. Despite this, the stock rose by 4.04% the next day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Mirum can demonstrate significant progress in its drug pipeline or show unexpected revenue growth, it could lead to a strong positive reaction from investors.

Bear Case

Conversely, if the company continues to report large losses or fails to provide clarity on its future prospects, it could lead to a negative response from the market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of the drug pipeline and expected timelines for upcoming trials?

Investors will closely watch for any updates that could indicate future revenue potential or setbacks.

How does the company plan to address the significant losses reported in the last quarter?

Understanding the company's strategy for managing expenses and improving profitability will be crucial for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

Supporting Evidence

The options market is pricing a 37.56% move, indicating expectations of volatility that may not align with historical performance.

Insider selling activity could suggest a lack of confidence in the near-term outlook, which the market may not fully appreciate.

Key Risk

If the company provides a clear and compelling update on its pipeline, it could shift the market's perception significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around whether Mirum can turn its financial performance around and make progress in its drug development pipeline.

Bull Confirmed If

Demonstrating a clear path to profitability with reduced losses or positive revenue growth would confirm the bull case.

Bear Confirmed If

Continued large losses without a clear strategy for improvement would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±37.56%

Historical Avg

±1.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings report.

Options are pricing ±37.6% while MIRM has averaged ±1.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

56.0%

Calls (10K)P/C Ratio: 3.33Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$193,800.00

2,000 sh

1 insider

Net

$193,800.00

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Mirum beats expectations and raises guidance, history suggests the stock could rise by around 1.33%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may see muted movement as investors reassess.

Miss

Should the company miss expectations again, history suggests an average decline of around 0.31%, indicating a negative reaction.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the timelines for clinical trials in the drug pipeline.
2Details on cost management strategies to address recent losses.
3Insights into market demand for their current and upcoming products.
4Comments on competitive landscape and how Mirum plans to differentiate itself.
5Any potential partnerships or collaborations that could enhance growth prospects.